10x Genomics Inc
For the period ended Mar 31, 2024. Filed Apr 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 30, 2024
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(59,949) | $(50,747) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 36,129 | 42,101 |
| Depreciation and amortization | 9,194 | 6,482 |
| Amortization of right-of-use assets | 2,300 | 2,134 |
| Lease and asset impairment charges | 2,454 | — |
| Realized loss on marketable securities | — | 1,715 |
| Other | 444 | 150 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 23,516 | 26,279 |
| Inventory | (9,937) | (449) |
| Prepaid expenses and other current assets | (2,029) | (4,253) |
| Other noncurrent assets | 216 | (10,470) |
| Accounts payable | 4,583 | (781) |
| Accrued compensation and other related benefits | (9,380) | (15,129) |
| Deferred revenue | 2,120 | 1,051 |
| Accrued expenses and other current liabilities | (12,674) | (161) |
| Operating lease liability | (2,961) | (2,308) |
| Other noncurrent liabilities | 249 | 261 |
| Net cash used in operating activities | (15,725) | (4,125) |
| Investing activities: | ||
| Purchases of property and equipment | (2,910) | (4,559) |
| Purchases of intangible assets | — | (723) |
| Proceeds from sales of marketable securities | 568 | 93,342 |
| Proceeds from maturities of marketable securities | 12,974 | 31,896 |
| Net cash provided by investing activities | 10,632 | 119,956 |
| Financing activities: | ||
| Payments on financing arrangement | — | (5,814) |
| Issuance of common stock from exercise of stock options | 1,638 | 2,400 |
| Net cash provided by (used in) financing activities | 1,638 | (3,414) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (48) | 24 |
| Net increase (decrease) in cash and cash equivalents | (3,503) | 112,441 |
| Cash and cash equivalents at beginning of period | 359,284 | 227,353 |
| Cash and cash equivalents at end of period | $355,781 | $339,794 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for interest | $— | $436 |
| Cash paid for taxes | $961 | $2,547 |
| Noncash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $1,899 | $30,668 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $6,893 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.